I had the pleasure of speaking to lawmakers at a Capitol Hill briefing to advocate for kidney disease patients to have better access to certain life-saving medications. The National Minority Quality Forum Action Network (NMQFAN) hosted a briefing for
Congressional Staff Patient Advocates, medical stakeholders, and health equity leaders to discuss impending restrictions on critical medicine for kidney dialysis patients and the urgent need for congressional action on the Kidney Patient Act of 2023 to maintain equitable access to quality care in Medicare’s End Stage Renal Disease (ESRD) payment plan.
This briefing was a crucial opportunity to highlight the disparities and challenges faced by kidney disease patients, particularly those from minority communities.
Despite significant advances in medical technology and treatment options, disparities in access to care for kidney disease patients persist. Research has shown that individuals from racial and ethnic minorities are more likely to develop kidney disease and experience poorer health outcomes compared to their white counterparts.
This is a critical issue that must be addressed to ensure equitable access to care for all kidney disease patients, regardless of race or socioeconomic status.
As leaders in the healthcare industry, it is our responsibility to advocate for policies that promote health equity and eliminate disparities in care. This includes supporting legislation such as the Kidney Patient Act of 2023, which aims to improve access to quality care for Medicare beneficiaries with kidney disease.
I was honored to be a speaker at this briefing along with Dr. Gary Puckrein, President and CEO of NMQFAN, Dr. Patrick Gee, Sr. Kidney Patient Advocate, and Dr. Laura Williams, Chief Medical Officer, Ardelyx.
- 17 Easy Ways To Lower Blood Pressure with Simple Diet and Lifestyle Changes - February 4, 2024
- Capitol Hill Briefing on Kidney Disease Health Equity | Dr. Frita McRae Fisher Speaks - January 31, 2024
- 10 Chronic Kidney Disease Symptoms You Should Refuse To Ignore! - January 24, 2024